The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Study to Learn About the Study Medicine Called PF-07799544 in People With Advanced Solid Tumors
Official Title: A PHASE 1A/B OPEN-LABEL MASTER STUDY OF PF-07799544 AS A SINGLE-AGENT AND IN COMBINATION WITH OTHER TARGETED AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS
Study ID: NCT05538130
Brief Summary: The purpose of this clinical trial is to learn the safety and effects of the study medicine (PF-07799544) administered as a single agent and in combination with other study medications in people with solid tumors. This study is seeking participants who have an advanced solid tumor for which the available treatments are no longer effective in controlling their cancer. All participants in this study will receive PF-07799544. PF-07799544 comes as a tablet to take by mouth daily (initially 2 times per day, but this could change to once daily or another frequency). Depending on the part of the study, participants may also receive another study medicine. * In the first part of the study, people with melanoma or other solid tumors may also receive encorafenib. Encorafenib comes as a capsule and is taken once per day. * In the second part of the study, people with melanoma or other cancers with abnormalities in a gene called "BRAF" will receive PF-07799544 with other study medicines (for example, PF-07799933). Participants may receive the study medicines for about 2 years. The study team will monitor how each participant is doing with the study treatment during regular visits at the study clinic.
Detailed Description:
Minimum Age: 16 Years
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Highlands Oncology Group, PA, Fayetteville, Arkansas, United States
Highlands Oncology Group, Fayetteville, Arkansas, United States
Highlands Oncology Group, PA, Rogers, Arkansas, United States
Highlands Oncology Group, Rogers, Arkansas, United States
Highlands Oncology Group, PA, Springdale, Arkansas, United States
Highlands Oncology Group, Springdale, Arkansas, United States
Highlands Oncology, Springdale, Arkansas, United States
Moffitt Cancer Center, Richard M. Shulze Family Foundation Outpatient Center, Tampa, Florida, United States
Moffitt Cancer Center, Tampa, Florida, United States
Moffitt McKinley Hospital, Tampa, Florida, United States
Florida Eye Center at Florida Medical Clinic, Tampa, Florida, United States
Brigitte Harris Cancer Pavilion, Detroit, Michigan, United States
Henry Ford Hospital, Detroit, Michigan, United States
Columbia University Irving Medical Center, New York, New York, United States
CUIMC Research Pharmacy, New York, New York, United States
Cleveland Clinic Taussig Cancer Center Investigational Pharmacy, Cleveland, Ohio, United States
Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States
Providence Cancer Institute Franz Clinic, Portland, Oregon, United States
Providence Portland Medical Center, Portland, Oregon, United States
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Fred Hutchinson Cancer Center, Seattle, Washington, United States
University of Washington Medical Center, Seattle, Washington, United States
Cross Cancer Institute, Edmonton, Alberta, Canada
The Ottawa Hospital - General Campus, Ottawa, Ontario, Canada
Sunnybrook Research Institute, Toronto, Ontario, Canada
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Jewish General Hospital, Montreal, Quebec, Canada
McGill University Health Centre, Montréal, Quebec, Canada
Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus, Quebec City, Quebec, Canada
Name: Pfizer CT.gov Call Center
Affiliation: Pfizer
Role: STUDY_DIRECTOR